
Martina Sester

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/230375/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Case report: cerebral sinus vein thrombosis in two patients with AstraZeneca SARS-CoV-2 vaccination. Journal of Neurology, 2022, 269, 583-586.	1.8	6
2	Ways to boost cellular immunity in solid organ transplant recipients – The case of letermovir. Transplant Infectious Disease, 2022, 24, .	0.7	1
3	Boosting immunity after CoronaVac. Lancet, The, 2022, 399, 496-497.	6.3	4
4	Immunogenicity and reactogenicity of homologous mRNA-based and vector-based SARS-CoV-2 vaccine regimens in patients receiving maintenance dialysis. Clinical Immunology, 2022, 236, 108961.	1.4	9
5	Data on immunogenicity and reactogenicity to COVID-19 vaccination among patients receiving maintenance dialysis. Data in Brief, 2022, 42, 108271.	0.5	1
6	Effect of everolimusâ€based drug regimens on CMVâ€specific Tâ€cell functionality after renal transplantation: 12â€month ATHENA subcohortâ€study results. European Journal of Immunology, 2021, 51, 943-955.	1.6	9
7	Impact of COVID-19 in solid organ transplant recipients. American Journal of Transplantation, 2021, 21, 925-937.	2.6	98
8	Diversity of antibody responses after influenza infection or vaccination—Needed or nice to have?. American Journal of Transplantation, 2021, 21, 2631-2632.	2.6	1
9	The future of SARSâ€CoVâ€2 vaccines in transplant recipients: To be determined. American Journal of Transplantation, 2021, 21, 2629-2630.	2.6	6
10	Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination. Nature Medicine, 2021, 27, 1530-1535.	15.2	276
11	Unpacking the COVIDâ€19 vaccine responses: Do we have what we need for a successful trip?. American Journal of Transplantation, 2021, 21, 3827-3828.	2.6	0
12	Cellular immunity predominates over humoral immunity after homologous and heterologous mRNA and vector-based COVID-19 vaccine regimens in solid organ transplant recipients. American Journal of Transplantation, 2021, 21, 3990-4002.	2.6	124
13	Elite athletes on regular training show more pronounced induction of vaccine-specific T-cells and antibodies after tetravalent influenza vaccination than controls. Brain, Behavior, and Immunity, 2020, 83, 135-145.	2.0	27
14	Apolipoprotein C3 induces inflammation and organ damage by alternative inflammasome activation. Nature Immunology, 2020, 21, 30-41.	7.0	169
15	Quantitative and time-resolved miRNA pattern of early human T cell activation. Nucleic Acids Research, 2020, 48, 10164-10183.	6.5	12
16	Discovery and validation of a personalized risk predictor for incident tuberculosis in low transmission settings. Nature Medicine, 2020, 26, 1941-1949.	15.2	58
17	Wrinkle in the plan: miR-34a-5p impacts chemokine signaling by modulating CXCL10/CXCL11/CXCR3-axis in CD4 ⁺ , CD8 ⁺ T cells, and M1 macrophages. , 2020, 8, e001617.		28
18	Prolonged Course of COVID-19-Associated Pneumonia in a B-Cell Depleted Patient After Rituximab. Frontiers in Oncology, 2020, 10, 1578.	1.3	44

#	Article	IF	CITATIONS
19	BK Polyomavirus-specific T Cells as a Diagnostic and Prognostic Marker for BK Polyomavirus Infections After Pediatric Kidney Transplantation. Transplantation, 2020, 104, 2393-2402.	0.5	11
20	A Polyclonal Immune Function Assay Allows Dose-Dependent Characterization of Immunosuppressive Drug Effects but Has Limited Clinical Utility for Predicting Infection on an Individual Basis. Frontiers in Immunology, 2020, 11, 916.	2.2	1
21	Timing of Vaccination after Training: Immune Response and Side Effects in Athletes. Medicine and Science in Sports and Exercise, 2020, 52, 1603-1609.	0.2	13
22	High-dose intranasal application of titanium dioxide nanoparticles induces the systemic uptakes and allergic airway inflammation in asthmatic mice. Respiratory Research, 2020, 21, 168.	1.4	13
23	Case Report: Management of a Multidrug-Resistant CMV-Strain in a Renal Transplant Recipient by High-Dose CMV-Specific Immunoglobulins, Modulation in Immunosuppression, and Induction of CMV-Specific Cellular Immunity. Frontiers in Immunology, 2020, 11, 623178.	2.2	1
24	High levels of SARS-CoV-2–specific T cells with restricted functionality in severe courses of COVID-19. JCI Insight, 2020, 5, .	2.3	97
25	miR-34a as hub of T cell regulation networks. , 2019, 7, 187.		29
26	CMV-specific T-cells and CD27-CD28-CD4+ T-cells for assignment of cytomegalovirus (CMV) status in adults awaiting organ transplant. Journal of Clinical Virology, 2019, 115, 37-42.	1.6	5
27	miR-34a: a new player in the regulation of T cell function by modulation of NF-κB signaling. Cell Death and Disease, 2019, 10, 46.	2.7	58
28	Novel human sex-typing strategies based on the autism candidate gene NLGN4X and its male-specific gametologue NLGN4Y. Biology of Sex Differences, 2019, 10, 62.	1.8	6
29	Tuberculosis in immunocompromised patients. , 2019, , 429-432.		0
30	Rapid reconstitution of <scp>CMV</scp> â€specific Tâ€cells after stemâ€cell transplantation. European Journal of Haematology, 2018, 101, 38-47.	1.1	4
31	Assay for improved detection of antigenâ€specific immune cells from extrasanguinous fluids. European Journal of Immunology, 2018, 48, 1412-1414.	1.6	2
32	CTLAâ€4â€expression on VZVâ€specific T cells in CSF and blood is specifically increased in patients with VZV related central nervous system infections. European Journal of Immunology, 2018, 48, 151-160.	1.6	13
33	VZV-specific T-cell levels in patients with rheumatic diseases are reduced and differentially influenced by antirheumatic drugs. Arthritis Research and Therapy, 2018, 20, 252.	1.6	8
34	Quantity, quality, and functionality of peripheral blood cells derived from residual blood of different apheresis kits. Transfusion, 2018, 58, 1516-1526.	0.8	19
35	Assigning Cytomegalovirus Status in Children Awaiting Organ Transplant: Viral Shedding, CMV-Specific T Cells, and CD27â^'CD28â^'CD4+ T Cells. Journal of Infectious Diseases, 2018, 218, 1205-1209.	1.9	13
36	Robust method for isolation of tumor infiltrating lymphocytes with a high vital cell yield from small samples of renal cell carcinomas by a new collagenase-free mechanical procedure. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 402.e1-402.e10.	0.8	5

#	Article	IF	CITATIONS
37	Testing for LTBI: more of the same or a step forward?. International Journal of Tuberculosis and Lung Disease, 2018, 22, 591-591.	0.6	1
38	Donorâ€specific alloreactive T cells can be quantified from whole blood, and may predict cellular rejection after renal transplantation. European Journal of Immunology, 2017, 47, 1220-1231.	1.6	8
39	Letter to the Editor regarding Dounousi E <i>et al</i> . Intact <scp>FGF</scp> 23 and αâ€Klotho during acute inflammation/sepsis in <scp>CKD</scp> patients. European Journal of Clinical Investigation, 2017, 47, 468-469.	1.7	2
40	Evaluation of antigen specific interleukin-1β as a biomarker to detect cattle infected with Mycobacterium bovis. Tuberculosis, 2017, 105, 53-59.	0.8	11
41	Quantitative, Phenotypical, and Functional Characterization of Cellular Immunity in Children and Adolescents With Down Syndrome. Journal of Infectious Diseases, 2017, 215, 1619-1628.	1.9	37
42	Decreased Migration of Dendritic Cells into the Jugular-Nodose Ganglia by the CXCL12 Neutraligand Chalcone 4 in Ovalbumin-Sensitized Asthmatic Mice. NeuroImmunoModulation, 2017, 24, 331-340.	0.9	6
43	Treatment of Cytomegalovirus Infection with Cidofovir and CMV Immune Globulin in a Lung Transplant Recipient. Case Reports in Transplantation, 2016, 2016, 1-4.	0.1	9
44	Viral Load and Risk of Tuberculosis in HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 71, e51-e53.	0.9	10
45	Steroid Treatment Reduces Allergic Airway Inflammation and Does Not Alter the Increased Numbers of Dendritic Cells and Calcitonin Gene-Related Peptide-Expressing Neurons in Airway Sensory Ganglia. NeuroImmunoModulation, 2016, 23, 18-26.	0.9	6
46	Increase of Mast Cell-Nerve Association and Neuropeptide Receptor Expression on Mast Cells in Perennial Allergic Rhinitis. NeuroImmunoModulation, 2016, 23, 261-270.	0.9	25
47	Impact of individual intravenous iron preparations on the differentiation of monocytes towards macrophages and dendritic cells. Nephrology Dialysis Transplantation, 2016, 31, 1835-1845.	0.4	23
48	Immune-based guidance of foscarnet treatment duration in a transplant recipient with ganciclovir-resistant cytomegalovirus infection. Journal of Clinical Virology, 2016, 82, 5-8.	1.6	5
49	What defines latent infection with <i>Mycobacterium tuberculosis</i> in patients with autoimmune diseases?. Thorax, 2016, 71, 3-4.	2.7	11
50	Clinical Application of Interferon-Î ³ Release Assays for the Prevention of Tuberculosis in Countries with Low Incidence. Pathogens and Immunity, 2016, 1, 308.	1.4	16
51	Alloreactive T Cells to Identify Risk HLA Alleles for Retransplantation After Acute Accelerated Steroid-Resistant Rejection. Transplantation Proceedings, 2015, 47, 2425-2432.	0.3	2
52	Superior Sensitivity of Ex Vivo IFN-Î ³ Release Assays as Compared to Skin Testing in Immunocompromised Patients. American Journal of Transplantation, 2015, 15, 2616-2624.	2.6	14
53	Numbers needed to treat to prevent tuberculosis. European Respiratory Journal, 2015, 46, 1836-1838.	3.1	28
54	Altered Phenotype and Functionality of Varicella Zoster Virus–Specific Cellular Immunity in Individuals With Active Infection. Journal of Infectious Diseases, 2015, 211, 600-612.	1.9	62

#	Article	IF	CITATIONS
55	Calcineurin inhibitors differentially alter the circadian rhythm of T-cell functionality in transplant recipients. Journal of Translational Medicine, 2015, 13, 51.	1.8	16
56	MHC/Peptide-Specific Interaction of the Humoral Immune System: A New Category of Antibodies. Journal of Immunology, 2015, 195, 4210-4217.	0.4	1
57	Revisiting Healthcare Workers as a Risk Group for Progression toward Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 1021-1022.	2.5	1
58	Development of an improved ESAT-6 and CFP-10 peptide-based cytokine flow cytometric assay for bovine tuberculosis. Comparative Immunology, Microbiology and Infectious Diseases, 2015, 42, 1-7.	0.7	15
59	Differentiation of Monocyte Derived Dendritic Cells in End Stage Renal Disease is Skewed Towards Accelerated Maturation. Advances in Clinical and Experimental Medicine, 2015, 24, 257-266.	0.6	10
60	Differentiation of monocyte derived Dendritic cells in End Stage Renal Disease is skewed towards accelerated maturation. Advances in Clinical and Experimental Medicine, 2015, 24, 257-266.	0.6	3
61	BK Polyomavirus-Specific Cellular Immune Responses Are Age-Dependent and Strongly Correlate With Phases of Virus Replication. American Journal of Transplantation, 2014, 14, 1334-1345.	2.6	65
62	Comparative Analysis of Assays for Detection of Cell-Mediated Immunity Toward Cytomegalovirus and M. tuberculosis in Samples From Deceased Organ Donors. American Journal of Transplantation, 2014, 14, 2159-2167.	2.6	25
63	Risk Assessment of Tuberculosis in Immunocompromised Patients. A TBNET Study. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 1168-1176.	2.5	196
64	A multicenter, randomized, open-labeled study to steer immunosuppressive and antiviral therapy by measurement of virus (CMV, ADV, HSV)-specific T cells in addition to determination of trough levels of immunosuppressants in pediatric kidney allograft recipients (IVIST01-trial): study protocol for a randomized controlled trial. Trials, 2014, 15, 324.	0.7	14
65	Detection of Antigen-Specific T Cells Based on Intracellular Cytokine Staining Using Flow-Cytometry. Methods in Molecular Biology, 2013, 1064, 267-274.	0.4	18
66	PD-1 Analysis on CD28â^'CD27â^' CD4 T Cells Allows Stimulation-Independent Assessment of CMV Viremic Episodes in Transplant Recipients. American Journal of Transplantation, 2013, 13, 3132-3141.	2.6	26
67	A unique secreted adenovirus E3 protein binds to the leukocyte common antigen CD45 and modulates leukocyte functions. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E4884-93.	3.3	45
68	Serial influenza-vaccination reveals impaired maintenance of specific T-cell memory in patients with end-stage renal failure. Vaccine, 2013, 31, 4111-4120.	1.7	20
69	Diagnosis and treatment of latent infection with <i><scp>M</scp>ycobacterium tuberculosis</i> . Respirology, 2013, 18, 205-216.	1.3	40
70	The Transmembrane Domain of the Adenovirus E3/19K Protein Acts as an Endoplasmic Reticulum Retention Signal and Contributes to Intracellular Sequestration of Major Histocompatibility Complex Class I Molecules. Journal of Virology, 2013, 87, 6104-6117.	1.5	21
71	Blockade of programmed death receptorâ€1 signaling restores expression of mostly proinflammatory cytokines in anergic cytomegalovirusâ€specific T cells. Transplant Infectious Disease, 2013, 15, 79-89.	0.7	28
72	Different Munc13 Isoforms Function as Priming Factors in Lytic Granule Release from Murine Cytotoxic T Lymphocytes. Traffic, 2013, 14, 798-809.	1.3	28

#	Article	IF	CITATIONS
73	Cytomegalovirusâ€specific <scp>T</scp> cells are detectable in early childhood and allow assignment of the infection status in children with passive maternal antibodies. European Journal of Immunology, 2013, 43, 1099-1108.	1.6	21
74	European survey on the management of tuberculosis in solid-organ transplant recipients and candidates. Transplant International, 2013, 26, e69-e70.	0.8	10
75	Antigen-Specific CD4 T Cells Are Induced after Intravesical BCG-Instillation Therapy in Patients with Bladder Cancer and Show Similar Cytokine Profiles as in Active Tuberculosis. PLoS ONE, 2013, 8, e69892.	1.1	23
76	Massive monoclonal expansion of CD4 T-cells specific for a <i>Mycobacterium tuberculosis</i> ESAT-6 peptide. European Respiratory Journal, 2012, 40, 152-160.	3.1	8
77	The risk of tuberculosis in transplant candidates and recipients: a TBNET consensus statement. European Respiratory Journal, 2012, 40, 990-1013.	3.1	211
78	Mutated Ras-Transfected, EBV-Transformed Lymphoblastoid Cell Lines as a Model Tumor Vaccine for Boosting T-Cell Responses Against Pancreatic Cancer: A Pilot Trial. Human Gene Therapy, 2012, 23, 1224-1236.	1.4	17
79	Screening for latent infection withMycobacterium tuberculosis: a plea for targeted testing in low endemic regions. Expert Review of Molecular Diagnostics, 2012, 12, 231-234.	1.5	6
80	Pathogen prevalence may determine maintenance of antigen-specific T-cell responses in HIV-infected individuals. Aids, 2012, 26, 695-700.	1.0	1
81	Diagnosis and Management of Tuberculosis in Transplant Donors: A Donor-Derived Infections Consensus Conference Report. American Journal of Transplantation, 2012, 12, 2288-2300.	2.6	121
82	TB or not TB: The role of immunodiagnosis. European Journal of Immunology, 2012, 42, 2840-2843.	1.6	2
83	Monocyte heterogeneity in human cardiovascular disease. Immunobiology, 2012, 217, 1273-1284.	0.8	114
84	The influence of immunosuppressive agents on BK virus risk following kidney transplantation, and implications for choice of regimen. Transplantation Reviews, 2012, 26, 201-211.	1.2	65
85	Cytomegalovirus-specific T-cell immunity to assign the infection status in individuals with passive immunity: A proof of principle. Journal of Clinical Virology, 2012, 54, 272-275.	1.6	19
86	Tuberculosis in Transplantation: Diagnosis, Prevention, and Treatment. Current Infectious Disease Reports, 2012, 14, 650-657.	1.3	9
87	T-cell Numbers and Antigen-specific T-cell Function Follow Different Circadian Rhythms. Journal of Clinical Immunology, 2012, 32, 1381-1389.	2.0	43
88	<scp>CD</scp> 4 ⁺ <scp>T</scp> â€cell immunity after pandemic influenza vaccination crossâ€reacts with seasonal antigens and functionally differs from active influenza infection. European Journal of Immunology, 2012, 42, 1755-1766.	1.6	31
89	TB in the immunocompromised host. , 2012, , 230-241.		1
90	Interferon-Â release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis. European Respiratory Journal, 2011, 37, 100-111.	3.1	488

#	Article	IF	CITATIONS
91	Whole-Blood Flow-Cytometric Analysis of Antigen-Specific CD4 T-Cell Cytokine Profiles Distinguishes Active Tuberculosis from Non-Active States. PLoS ONE, 2011, 6, e17813.	1.1	109
92	World-Wide Challenges and Perspectives for Handling HIV/Mycobacterium tuberculosis Co-Infections. The Open Infectious Diseases Journal, 2011, 5, 13-13.	0.6	0
93	Challenges and perspectives for improved management of HIV/Mycobacterium tuberculosis co-infection. European Respiratory Journal, 2010, 36, 1242-1247.	3.1	39
94	Management of tuberculosis in HIV infection: where T-cells matter. European Respiratory Journal, 2010, 35, 475-476.	3.1	7
95	Conserved Amino Acids within the Adenovirus 2 E3/19K Protein Differentially Affect Downregulation of MHC Class I and MICA/B Proteins. Journal of Immunology, 2010, 184, 255-267.	0.4	21
96	The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. European Respiratory Journal, 2010, 36, 1185-1206.	3.1	444
97	Successful outcome of kidney transplantation from a HBV-DNA positive donor into recipients with cleared HBV-infection using a pre-emptive therapy approach. Journal of Clinical Virology, 2010, 49, 53-57.	1.6	10
98	Differential kinetics of effector and regulatory T cells in patients on calcineurin inhibitor–based drug regimens. Kidney International, 2009, 76, 557-566.	2.6	41
99	Impaired detection of Mycobacterium tuberculosis immunity in patients using high levels of immunosuppressive drugs. European Respiratory Journal, 2009, 34, 702-710.	3.1	45
100	LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. European Respiratory Journal, 2009, 33, 956-973.	3.1	487
101	PD-1 Expression and IL-2 Loss of Cytomegalovirus- Specific T Cells Correlates with Viremia and Reversible Functional Anergy. American Journal of Transplantation, 2008, 8, 1486-1497.	2.6	145
102	Vaccination of the solid organ transplant recipient. Transplantation Reviews, 2008, 22, 274-284.	1.2	47
103	Cytomegalovirus-specific T-cell responses and viral replication in kidney transplant recipients. Journal of Translational Medicine, 2008, 6, 29.	1.8	103
104	Structural analysis of the adenovirus type 2 E3/19K protein using mutagenesis and a panel of conformation-sensitive monoclonal antibodies. Molecular Immunology, 2008, 46, 16-26.	1.0	7
105	Monitoring of CMV-specific T-cell levels after organ transplantation / Monitoring CMV-spezifischer T-Zellen nach Organtransplantation. Laboratoriums Medizin, 2008, 32, 121-130.	0.1	0
106	Adenovirus E3/19K Promotes Evasion of NK Cell Recognition by Intracellular Sequestration of the NKG2D Ligands Major Histocompatibility Complex Class I Chain-Related Proteins A and B. Journal of Virology, 2008, 82, 4585-4594.	1.5	95
107	Levels of CMV Specific CD4 T Cells Are Dynamic and Correlate with CMV Viremia after Allogeneic Stem Cell Transplantation. PLoS ONE, 2008, 3, e3634.	1.1	75
108	Maintenance of HIV-Specific Central and Effector Memory CD4 and CD8 T Cells Requires Antigen Persistence. AIDS Research and Human Retroviruses, 2007, 23, 549-553.	0.5	12

#	Article	IF	CITATIONS
109	Estimation of Human Herpesvirus 8 Prevalence in High-Risk Patients by Analysis of Humoral and Cellular Immunity. Transplantation, 2007, 84, 40-45.	0.5	8
110	Numerical modelling of label-structured cell population growth using CFSE distribution data. Theoretical Biology and Medical Modelling, 2007, 4, 26.	2.1	54
111	Simultaneous ex vivo quantification of antigen-specific CD4+ and CD8+ T cell responses using in vitro transcribed RNA. Cancer Immunology, Immunotherapy, 2007, 56, 1577-1587.	2.0	46
112	Humoral immune responses of lung cancer patients against tumor antigen NY-ESO-1. Cancer Letters, 2006, 236, 64-71.	3.2	71
113	Antigen-specific T cell responses: Determination of their frequencies, homing properties, and effector functions in human whole blood. Methods, 2006, 38, 77-83.	1.9	12
114	Improved efficiency in detecting cellular immunity towards M. tuberculosis in patients receiving immunosuppressive drug therapy. Nephrology Dialysis Transplantation, 2006, 21, 3258-3268.	0.4	46
115	Dynamics of CD81 expression on lymphocyte subsets during interferon-Â-based antiviral treatment of patients with chronic hepatitis C. Journal of Leukocyte Biology, 2006, 80, 298-308.	1.5	10
116	Naturally occurring T-cell response against mutated p21 ras oncoprotein in pancreatic cancer Clinical Cancer Research, 2006, 12, 1365-1372.	3.2	50
117	Differences in CMV-Specific T-Cell Levels and Long-Term Susceptibility to CMV Infection after Kidney, Heart and Lung Transplantation. American Journal of Transplantation, 2005, 5, 1483-1489.	2.6	140
118	Tuberculin skin testing underestimates a high prevalence of latent tuberculosis infection in hemodialysis patients. Kidney International, 2004, 65, 1826-1834.	2.6	93
119	Rapid Identification of Preformed Alloreactive T Cells for Use in a Clinical Setting. Transplantation, 2004, 78, 607-614.	0.5	6
120	Transforming growth factor β1 genotype polymorphisms determine AV fistula patency in hemodialysis patients. Kidney International, 2003, 64, 1101-1107.	2.6	62
121	Uremia-associated immune defect: The IL-10–CRP axis. Kidney International, 2003, 63, S76-S79.	2.6	37
122	Is the cytomegalovirus serologic status always accurate? A comparative analysis of humoral and cellular immunity1. Transplantation, 2003, 76, 1229-1231.	0.5	58
123	Sustained High Frequencies of Specific CD4 T Cells Restricted to a Single Persistent Virus. Journal of Virology, 2002, 76, 3748-3755.	1.5	107
124	Evaluation of Use of Epstein-Barr Viral Load in Patients after Allogeneic Stem Cell Transplantation To Diagnose and Monitor Posttransplant Lymphoproliferative Disease. Journal of Clinical Microbiology, 2002, 40, 351-358.	1.8	104
125	A shift in the Th1/Th2 ratio accompanies the clinical remission of systemic lupus erythematosus in patients with end-stage renal disease. Nephrology Dialysis Transplantation, 2002, 17, 1790-1794.	0.4	21
126	Ageâ€Related Decrease in Adenovirusâ€Specific T Cell Responses. Journal of Infectious Diseases, 2002, 185, 1379-1387.	1.9	56

#	Article	IF	CITATIONS
127	Dominance of Virus-Specific CD8 T Cells in Human Primary Cytomegalovirus Infection. Journal of the American Society of Nephrology: JASN, 2002, 13, 2577-2584.	3.0	101
128	The fraction of perforin-expressing HIV-specific CD8 T cells is a marker for disease progression in HIV infection. Aids, 2002, 16, 1497-1501.	1.0	44
129	Anti-inflammatory interleukin-10 genotype protects dialysis patients from cardiovascular events. Kidney International, 2002, 62, 949-955.	2.6	128
130	Evaluation of Use of Epstein-Barr Viral Load in Patients after Allogeneic Stem Cell Transplantation To Diagnose and Monitor Posttransplant Lymphoproliferative Disease. Journal of Clinical Microbiology, 2002, 40, 2316-2316.	1.8	0
131	Selective sequestration of cytokine-producing monocytes during hemodialysis treatment. American Journal of Kidney Diseases, 2001, 37, 954-963.	2.1	22
132	LEVELS OF VIRUS-SPECIFIC CD4 T CELLS CORRELATE WITH CYTOMEGALOVIRUS CONTROL AND PREDICT VIRUS-INDUCED DISEASE AFTER RENAL TRANSPLANTATION1. Transplantation, 2001, 71, 1287-1294.	0.5	217
133	The interleukin-10 promoter genotype determines clinical immune function in hemodialysis patients. Kidney International, 2001, 60, 2385-2391.	2.6	58
134	Defective expression of B7-2 (CD86) on monocytes of dialysis patients correlates to the uremia-associated immune defect. Kidney International, 2001, 59, 1382-1389.	2.6	94
135	Molecular aspects of T – and B-cell function in uremia. Kidney International, 2001, 59, S206-S211.	2.6	142
136	Strong depletion of CD14+CD16+ monocytes during haemodialysis treatment. Nephrology Dialysis Transplantation, 2001, 16, 1402-1408.	0.4	65
137	Molecular aspects of T- and B-cell function in uremia. Kidney International, 2001, 59, 206-211.	2.6	75
138	Rapid whole blood analysis of virus-specific CD4 and CD8 T cell responses in persistent HIV infection. Aids, 2000, 14, 2653-2660.	1.0	28
139	The Amyloid Precursor-like Protein 2 Associates with the Major Histocompatibility Complex Class I Molecule Kd. Journal of Biological Chemistry, 2000, 275, 3645-3654.	1.6	30
140	Initiation of hemodialysis treatment leads to improvement of T-cell activation in patients with end-stage renal disease. American Journal of Kidney Diseases, 2000, 35, 611-616.	2.1	64
141	Prospective crossover trial of the influence of vitamin E–coated dialyzer membranes on T-cell activation and cytokine induction. American Journal of Kidney Diseases, 2000, 35, 95-104.	2.1	59
142	Tâ€cell activation follows Th1 rather than Th2 pattern in haemodialysis patients. Nephrology Dialysis Transplantation, 2000, 15, 1217-1223.	0.4	144
143	Impaired cellular immune function in patients with end-stage renal failure. Nephrology Dialysis Transplantation, 1999, 14, 2807-2810.	0.4	180
144	Activation of transcription factor NF-kappaB by the adenovirus E3/19K protein requires its ER retention Journal of Cell Biology, 1996, 132, 511-522.	2.3	161

#	Article	IF	CITATIONS
145	Humoral and cellular immune responses to the mRNA-1273 SARS-CoV-2 vaccine booster in patients on maintenance dialysis. Journal of Nephrology, 0, , .	0.9	4